Figure 1.
Timeline of the pharmacokinetic trial of rifabutin with antiretroviral treatment in HIV-infected patients with tuberculosis in Vietnam.
PK = pharmacokinetic analyses; TPW = three times per week; OD = once per Day; d4T = stavudine; 3TC = lamivudine; LPV/r = lopinavir/ritonavir; TB = tuberculosis; SCC = short course chemotherapy; RH = rifampicin and isoniazid; ART = antiretroviral therapy; EFV = efavirenz
Table 1.
Geometric mean ratios and 90% confidence intervals of rifabutin and 25-O desacetyl rifabutin parameters measured for rifabutin plus lopinavir/ritonavir and rifabutin.
Figure 2.
Patient Flow Chart for the trial.
PK = pharmacokinetic analyses
Table 2.
Base-line characteristics of HIV-infected tuberculosis patients in Vietnam.
Figure 3.
Plasma concentrations plotted against time for rifabutin (R) and 25 desacetyl rifabutin (D) in relation to whether rifabutin was administered alone (300 mg) or combined with lopinavir/ritonavir at 150 mg OD or TPW.
OD = once daily; TPW = three times per week
Table 3.
Pharmacokinetic parameters of rifabutin and 25-O desacetyl rifabutin.
Table 4.
Lopinavir and ritonavir pharmacokinetic parameters.
Table 5.
Serious adverse events in patients who completed all pharmacokinetic assessments (N = 25) and in patients who did not complete the assessments (N = 8).